Zai Lab (HKSE:09688) ROCE % : -40.72% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zai Lab ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zai Lab's annualized ROCE % for the quarter that ended in Dec. 2024 was -40.72%.

Zai Lab ROCE % Historical Data

The historical data trend for Zai Lab's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab ROCE % Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-35.44

-53.34

-35.45

-35.04

-29.57

Zai Lab Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-43.52	-26.22	-41.63	-22.79	-40.72

Zai Lab ROCE % Calculation

Zai Lab's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-1981.043	/	( ( (8093.257 - 1585.913)	+	(9217.332 - 2327.239) )	/ 2 )
	=	-1981.043	/	( (6507.344	+	6890.093)	/ 2 )
	=	-1981.043	/	6698.7185
	=	-29.57 %

Zai Lab's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-2511.74	/	( ( (7676.831 - 2230.68)	+	(9217.332 - 2327.239) )	/ 2 )
	=	-2511.74	/	( ( 5446.151	+	6890.093 )	/ 2 )
	=	-2511.74	/	6168.122
	=	-40.72 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Zai Lab (HKSE:09688) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zai Lab ROCE % Related Terms

Thank you for viewing the detailed overview of Zai Lab's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ZLAB:USA ZLAB N:Mexico 1ZLB:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Executives

Du Ying	2101 Beneficial owner
Fmr Llc	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Janus Henderson Group Plc	2102 Investment manager
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Invesco Advisers, Inc.	2102 Investment manager
Invesco Developing Markets Fund	2106 Person having a security interest in shares
Baillie Gifford & Co	2102 Investment manager
Citigroup Inc.	2502 Approved lending agent

Zai Lab Headlines

No Headlines